A 12-year-old girl with cystic fibrosis suffered from severe chronic lower respiratory tract infection. For several years she had been treated with elective 3-monthly intravenous antibiotic therapy for persistent respiratory Staphylococcus aureus infection. She was hospitalized earlier than scheduled for an additional course of intravenous antibiotic therapy because of deterioration of her respiratory infection, as evidenced by increased cough and sputum production. The latest sputum samples had grown S. aureus, She was treated with intravenous ceftazidime (300 mg/kg/ day), colomycin (0.6 mega units, taken three times a day) and tobramycin (starting dose 4.5mg/kg/day, increased to 13mg/kg/day according to drug levels), a regimen that had previously been used successfully. All three drugs were given 8-hourly and a 14-day treatment course was planned. On day 12 a permanent indwelling venous access device (Port-A-Cath) was inserted surgically to assist venous access. The antibiotic therapy was continued for a further 4 days to cover the postoperative period. Due for discharge on day 16, the patient suddenly developed fever spikes of up to 41.2°C, occurring cvery 8 h. Clinically there was no focus of infection, and between fevers she was well. Because of the possibility of ongoing respiratory infection the antibiotics were continued. This did not lead to clinical improvement, and the fever continued to spike at 8-hourly intervals. After 72 h of this febrile illness her full blood count started to show abnormalities; by day 20 her leukocyte count had dropped from 5.1 X 109/L (day 5) and 3.8 X 10 9/L (day 16) to 2.2 X 10 9/L (day 20) with a neutrophil count of only 0.8 X 10 9/L (day 20) (normal range leukocyte count:~3.5 X 10 9/L, ncutrophils 1.8 X 10 9 /L). Her platelet count dropped from 314x 10 9/L (day 5) and 198 X 10 9/L (day 16) to 69 X 10 9/L (day 20) (normal range 140-400 X 109/L). The haemoglobin fell from 12.1 g/dL (day 5) and 11.7 g/ dL (day 16) to 1O.4g/dL (day 20) (normal range 11.5 14.5 g/dL; a decrease by~10% is significant)!. At this stage the differential diagnoses for this illness had included the following:
The new intravenous access device, which was not considered to be a likely focus for sepsis, as four blood cultures from the line remained negative. In addition, the patient was very well in between fever spikes and the condition resolved without removal of the device or any additional antihiotic treatment 2 Septicaemia with another, unknown focus was also not deemed to be likely in the absence of positive blood cultures. Urine culture ( X I), sputum cultures (daily) and throat swabs (X 2) were obtained and remained negative. As mentioned above, she improved without further therapy, which makes bacterial sepsis unlikely 3 A lower respiratory tract infection was considered, hut clinically she had greatly improved by day 16. Daily sputum cultures showefl that there was no bacterial growth before and during the time when the fever was occurring. Chest X-rays showed resolution of the inflammatory findings from the time of admission, and now revealed long-standing changes only. The lower respiratory tract seemed an unlikely focus for such a severe fever and the concomitant bone marrow suppression 4 Viral illness was regarded as a plausible explanation for a combination of high fever and hone marrow suppression. However, the fever spikes were 8 hourly, were associated with the time of drug administration, and stopped immediately after cessation of ceftazidime. Clinically she had no signs of a viral illness and serology for cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), adenovirus, parvovirus and Coxsackie virus was negative (acute and convalescence samples) 5 Haematological disease was considered, specifically leukaemia or haemophagocytotic Iymphohistiocytotic syndrome. The course of events, however, showed an acute problem in a child with a normal blood count on admission and no past history of haematological compromise. The constellation of symptoms did not meet the criteria of haemophagocytotic syndrome. The blood film on day 19 showed 'a few atypical lymphocytes' only. The hlood film on day 22 was normal. All changes resolved within days of discontinuing the ceftazidime and her full blood count has since remained normal 6 A reaction to her multiple drugs was included in the different diagnosis, but her long-standing medication (Ketovite, Creon 10000, Gaviscon, cisapride, DNAse nebulizer, vitamin E, fluticasone and salbutamol inhalers) remained unchanged throughout the period before, during and after the fever, and hence were decided to be not causative. and tobramycin. The fever disappeared and did not recur after the ceftazidime was discontinued. Figure I shows the temperature curve, with black arrows denoting the time of administration of ceftazidime, including the final test dose.
The full blood count recovered to normal values within the following 5 days. We therefore concluded that the ceftazidime had led to a late-onset drug-induced fever with associated bone marrow suppression.
DISCUSSION
On day 19 the patient complained of chest tightness and cough during the administration of ceftazidime. To see if ceftazidime might be the causative agent of these symptoms, she was given a 'test dose' of the three antibiotics. Each agent was given without the patient being aware of the sequence of administration. A 20 mL bolus of 0.9% saline was followed by a slow bolus of 3 g ceftazidime (over 6 min), then another 20 mL of 0.9% saline, followed by 120 mg tobramycin (given over 5 min), again 20 mL saline and then 0.6 mega units of colomycin as an infusion over 30 min. The cough and chest tightness appeared towards the end of the bolus of ceftazidime. These symptoms were brief and subsided after 5 min. There was no wheezing audible. The other antibiotics caused no symptoms. Within 2 h the fever had risen to 39.6°C again. It was decided to discontinue the ceftazidime, but to continue the colornycin Drug-induced fever and bone marrow suppression are recognized complications of antibiotic therapy, but are only rarely seen together 2 ,3. Transient bone marrow suppression is thought to be caused by effects of the drugs on progenitor cells1,3,4. These toxic effects can be dose related and with respect to our case one needs to bear in mind that high doses of ceftazidime were used--", Direct cytotoxic drug effects, as well as immune-mediated damage to certain cell lines, have also been described l ,5,6. In most cases resolution of the bone marrow suppression tends to occur when the offending agent is stopped I 3. Drug-induced fever is seen as the sole adverse effect in 3-4% of all reported drug reactions 7 ,8. Older studies report lower incidences of drug fever, which could be explained by the increased and often prolonged use of newer generations of antibiotics'': 10. In the context of the yeliow card reporting scheme this number is also lower, and most probably reflects underreporting of the condition. The incidence of druginduced fever rises significantly with fJ-lactam antibiotics. Three to eight per cent of patients treated with first-and second-generation cephalosporins, 8-15% of those treated with third-generation cephalosporins and 17% of patients receiving piperacillin may develop drug-induced fever, which typically appears after 10--20 days of treatment'<l '. Pleasants et aJ.ll postulated that the incidence of drug-induced fever is even higher in patients with cystic fibrosis, i.e. up to 32% when fJ-lactam antibiotics are used. The underlying pathophysiology is still not well understood, although several immunological mechanisms have been proposed", The pattern of drug-induced fevers can vary from a stepwise increasing temperature (most common) to a remitting or intermittent fever l 2 . It can appear at a relatively fixed interval following each dose, as in our case. Clinical recognition can be made easier if certain diagnostic criteria are met, as in our case: the temperature should be recorded four times a day or more, no source of infection should be found, and any other underlying condition causing the fever ought to be excluded", The fever should coincide temporally with administration of the offending drug, and should disappear after discontinuation of that drug. The patient should then remain apyrexial. Confirmation of the drug as the causative agent with skin-prick testing is not possible, as the reaction is not IgE mediated, but rechallenging intravenously with the drug can confirm the diagnosis with a rapid recurrence of the fever 7 ,12. Our case is unusual because of the simultaneous occurrence of drug-induced fever and bone marrow suppression caused by ceftazidime. This has not previously been reported with ceftazidime, but has been observed for other {J-lactam antibiotics-v. Reichardt et aJ. observed druginduced fever in 6 out of 84 children treated with a combination of piperacillin and tazobactam. The fever occurred between days 11 and 15 of the treatment course, and one child developed neutropenia and thrombocytopenia after the onset of the fever. Full recovery took place after the cessation of therapy, as in our case.
This case serves as a reminder that drugs administered should always be considered and reported as a cause in a child with fever, bone marrow suppression or a combination of the two.
